Evolving role of irinotecan in small-cell lung cancer.

Clinical advances in hematology & oncology : H&O

Volumn 1, Issue 8, 2003, Pages 482-485

  Spigel, David R ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN;

DRUG SCREENING; HUMAN; LUNG TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SMALL CELL CARCINOMA; STATISTICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS;

EID: 33644814762     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)